Search Results for "Depression"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Depression. Results 201 to 210 of 379 total matches.
Alprazolam (Xanax, and others) Revisited
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005 (Issue 1200)
,
but have little effect on depressive symptoms.
3,4
These drugs are often combined for treatment of
panic ...
Alprazolam, a short-acting benzodiazepine, is one of the most widely prescribed drugs in the US. It is approved by the FDA for treatment of anxiety and panic disorder. An extended-release formulation, Xanax XR, which can be taken once a day, recently became available for panic disorder.
Ziconotide (Prialt) for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Dec 05, 2005 (Issue 1223)
was not reported.
INTERACTION WITH OPIOIDS — When ziconotide
is used with opioids or other CNS-depressant drugs ...
The FDA has approved ziconotide (Prialt - Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic neuronal N-type calcium channel blocker. It is intended for use with a programmable implanted microinfusion device, but an external microinfusion device can be used temporarily.
Nabilone (Cesamet) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
, dysphoria, depression, visual hallucinations and psychosis
can occur, especially in older patients ...
Nabilone, an oral synthetic cannabinoid similar to delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, has recently been reintroduced to the US market (Cesamet - Valeant) after a 17-year absence. The previous manufacturer discontinued marketing of the drug for commercial reasons. Nabilone is classified as a Schedule II controlled substance.
Tapentadol (Nucynta) - A New Analgesic
The Medical Letter on Drugs and Therapeutics • Aug 10, 2009 (Issue 1318)
— Taking tapentadol concomitantly with other CNS depressants could cause additive
CNS depression. Since ...
The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II controlled substance
Suvorexant (Belsomra) for Insomnia
The Medical Letter on Drugs and Therapeutics • Mar 02, 2015 (Issue 1463)
or other CNS depressants could result in additive
psychomotor and CNS-depressant effects.
CONCLUSION ...
The FDA has approved suvorexant (Belsomra –
Merck), the first orexin receptor antagonist to become
available in the US, for treatment of sleep-onset and/or
sleep-maintenance insomnia.
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019 (Issue 1576)
of
depression, but has some nicotinicreceptor-
blocking activity and may
also aid smoking cessation ...
View the Expanded Table: Some Drugs for Smoking Cessation
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
of these reactions. Pyrexia, hepatotoxicity,
sleep disturbances, and depression were also reported ...
The FDA has approved Cabenuva (ViiV Healthcare),
an extended-release formulation of the new integrase
strand transfer inhibitor (INSTI) cabotegravir
copackaged with an extended-release formulation
of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine, as a once-monthly complete
regimen for intramuscular (IM) treatment of adults
with HIV-1 infection who are virologically suppressed
(HIV-1 RNA...
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
, dizziness, fatigue, nausea, and vomiting. Psychiatric adverse effects (mainly anxiety and depression ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction
Methylphenidate Revisited
The Medical Letter on Drugs and Therapeutics • May 06, 1988 (Issue 765)
, and sensitivity to criticism that resembles depression.
OTHER DRUGS — Pemoline (Cylert) and dextroamphetamine ...
Methylphenidate (Ritalin and others), a Schedule II controlled substance in the USA, is a short-acting central-nervous-system stimulant widely used for treatment of children with school performance or behavior problems, or what is now called Attention Deficit-Hyperactivity Disorder, or AD-HD (American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, third ed., revised [DSM-III R], Washington, DC:authors, 1987, p 50). Some studies have estimated that more than 3% of elementary school students are taking methylphenidate, and one parents' group has brought a...
Altretamine For Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
, ataxia,
dizziness, vertigo, depression, personality changes, seizures, and hallucinations ...
Altretamine (Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
